Appropriate Use of Primary Statin Preventive Therapy Among Patients with High Atherosclerosis-Related Cardiovascular Disease Risks: Cross-Sectional Study, Northeast Ethiopia

References

• Toth PP, Banach M. Statins: then and now. Methodist Debakey Cardiovasc J. 2019;15(1):23. doi:10.14797/mdcj-15-1-23
   PubMedGoogle Scholar
• Celermajer DS, Chow CK, Marijon E, Anstey NM, Woo KS. Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection. J Am Coll Cardiol. 2012;60(14):1207–1216. doi:10.1016/j.jacc.2012.03.074
   PubMedGoogle Scholar
• Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison’s Principles of Internal Medicine. 19th ed. New York, NY, USA: Mcgraw-hill; 2015.
   Google Scholar
• Saeed A, Zhu J, Thoma F, et al. Cardiovascular disease risk–based statin utilization and associated outcomes in a primary prevention cohort: insights from a large health care network. Circ Cardiovasc Qual Outcomes. 2021;14(9):e007485. doi:10.1161/CIRCOUTCOMES.120.007485
   PubMed Web of Science ®Google Scholar
• Abukhalil AD, Alyan M, AbuAita W, Al-Shami N, Naseef HA. Adherence to clinical guidelines on STATIN prescribing among diabetic patients aged 40–75 years old in a primary care setting: a cross-sectional study. Patient Prefer Adherence. 2022;16:1855–1863. doi:10.2147/PPA.S376000
   PubMed Web of Science ®Google Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e563–e595. doi:10.1161/CIR.0000000000000677
   PubMed Web of Science ®Google Scholar
• Bates T, Connaughton V, Watts G. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009;10(18):2973–2985. doi:10.1517/14656560903376186
   PubMed Web of Science ®Google Scholar
• Chobufo MD, Regner SR, Zeb I, Lacoste JL, Virani SS, Balla S. Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017–2020. Eur J Prev Cardiol. 2022;29(14):1830–1838. doi:10.1093/eurjpc/zwac103
   PubMed Web of Science ®Google Scholar
• Brobbey FS, Malick MMD, Adjei S. Statin therapy prescribing patterns for primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus receiving primary care at the tamale teaching hospital (TTH) in Northern Ghana. EAS J Pharm Pharmacol. 2020;2:74–82.
   Google Scholar
• Bideberi AT, Mutagaywa R. Statin prescription patterns and associated factors among patients with type 2 diabetes mellitus attending diabetic clinic at Muhimbili National Hospital, Dar es Salaam, Tanzania. Diabetes Metabol Syndr Obes. 2022;15:633–646. doi:10.2147/DMSO.S347765
   PubMed Web of Science ®Google Scholar
• Go AS, Fan D, Sung SH, et al. Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: the KP CHAMP study. Am Heart J. 2017;194:25–38. doi:10.1016/j.ahj.2017.08.013
   PubMed Web of Science ®Google Scholar
• Sarfo FS, Ovbiagele B. Prevalence and predictors of statin utilization among patient populations at high vascular risk in Ghana. J Neurol Sci. 2020;414:116838. doi:10.1016/j.jns.2020.116838
   PubMed Web of Science ®Google Scholar
• Mwita JC, Godman B, Esterhuizen TM. Statin prescription among patients with type 2 diabetes in Botswana: findings and implications. BMC Endocr Disord. 2020;20(1):1–9. doi:10.1186/s12902-020-0516-7
   PubMed Web of Science ®Google Scholar
• Steen DL, Khan I, Becker L, et al. Patterns and predictors of lipid‐lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: insights from a large US managed‐care population. Clin Cardiol. 2017;40(3):155–162. doi:10.1002/clc.22641
   PubMed Web of Science ®Google Scholar
• Mohammed WK, Alwash SJ. Rate of prescribing statins for primary prevention of atherosclerotic cardiovascular disease in diabetic patients. Iraqi Postgraduate Med J. 2022;21(2):1–10.
   Google Scholar
• Wallach-Kildemoes H, Andersen M, Diderichsen F, Lange T. Adherence to preventive statin therapy according to socioeconomic position. Eur J Clin Pharmacol. 2013;69(8):1553–1563. doi:10.1007/s00228-013-1488-6
   PubMed Web of Science ®Google Scholar
• Bradley CK, Wang TY, Li S, et al. Patient‐reported reasons for declining or discontinuing statin therapy: insights from the PALM registry. J Am Heart Assoc. 2019;8(7):e011765. doi:10.1161/JAHA.118.011765
   PubMed Web of Science ®Google Scholar
• Jones N, Fischbacher C, Guthrie B, et al. Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006–2008. Diabetic Med. 2014;31(6):640–646. doi:10.1111/dme.12409
   PubMed Web of Science ®Google Scholar
• Berthold HK, Gouni-Berthold I, Böhm M, Krone W, Bestehorn KP. Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovasc Diabetol. 2009;8(1):1–12. doi:10.1186/1475-2840-8-25
   PubMedGoogle Scholar
• Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167(8):847–852. doi:10.1001/archinte.167.8.847
   PubMedGoogle Scholar
• Demoz GT, Wahdey S, Kasahun GG, et al. Prescribing pattern of statins for primary prevention of cardiovascular diseases in patients with type 2 diabetes: insights from Ethiopia. BMC Res Notes. 2019;12(1):1–7. doi:10.1186/s13104-019-4423-9
   PubMedGoogle Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127–e248. doi:10.1016/j.jacc.2017.11.006
   PubMed Web of Science ®Google Scholar
• Johnson R, Feehally J. Comprehensive Clinical Nephrology 6th Ed. Elsevier Health Science. 2019:493–494.
   Google Scholar
• Steen DL, Khan I, Ansell D, Sanchez RJ, Ray KK. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. BMJ open. 2017;7(2):e013255. doi:10.1136/bmjopen-2016-013255
   PubMed Web of Science ®Google Scholar
• Gupta R, Lodha S, Sharma KK, et al. Evaluation of statin prescriptions in type 2 diabetes: India Heart Watch-2. BMJ Open Diabetes Res Care. 2016;4(1):e000275. doi:10.1136/bmjdrc-2016-000275
   PubMed Web of Science ®Google Scholar
• Marcus ME, Manne-Goehler J, Theilmann M, et al. Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. Lancet Global Health. 2022;10(3):e369–e379. doi:10.1016/S2214-109X(21)00551-9
   PubMed Web of Science ®Google Scholar
• Feyisa D, Feyisa D. Determinants of statin initiation among adult diabetic patients in Bonga, Ethiopia. Diabetes Metabol Syndr Obes. 2020;13:4839. doi:10.2147/DMSO.S283993
   PubMed Web of Science ®Google Scholar
• Melaku T, Solomon Y, Chelkeba L. Statin utilization patterns among Type 2 diabetes mellitus patients with high cardiovascular disease risks in Ethiopia. J Pharm Care. 2018;6(3–4):44–51.
   Google Scholar